SWITZERLAND, SATURDAY, 25 APRIL 2020 8:30 PM CET
As the world’s first AI-biopharma company that has discovered and publicized the precise aetiology and pathology of COVID-191, we are committed to the non-profit dissemination of our COVID-19 discoveries and the public validation of our COVID-19 clinical predictions.
On 28 February 2020, we shared the pathology-based prospective prediction that the combination of irinotecan and etoposide could potentially be an exceptionally effective treatment to protect critically ill patients from death caused by COVID-19-specific cytokine storms triggered by sepsis, ARDS, and other fatal comorbidities1.
On 22 April 2020, a phase 2 clinical trial (NCT043566902) has been initiated by Boston Medical Center to investigate the safety and efficacy of etoposide in severely ill COVID-19 patients with clinical onset of cytokine storm. 134 participants will be recruited and allocated into two experimental arms based on ventilation, and their pulmonary status will be evaluated as the primary endpoint. The primary completion date is December 2020, and the topline result will be available in 2021.
In contrast to a growing list of COVID-19 therapeutic candidates that were empirically proposed and are struggling to prove efficacy and safety in clinical trials or compassionate uses4, etoposide is one of the few rationally discovered therapeutic candiates that are backed up by AI-discovered precise aetiology and pathology of COVID-19 that consistently explains patient-specific clinical features treatment-specific scientific rationales1.
It is much more important and urgent for European and American countries than for Asian countries to prioritize the clinical trials of effective and scalable treatments for critically ill patients, as our validated precise COVID-19 model shows that Americans/Europeans—with much lower baseline ACE2 expressions than East Asians—are much more prone to developing severe clinical outcomes because SARS-CoV-2 suppresses ACE2 expression for viral replication3.
Therefore, as the world’s first clinical trial that investigates etoposide for severely ill COVID-19 patients, NCT04356690 addresses one of the most pressing challenges for containing the COVID-19 pandemic.
1. Lovetrue, B. The AI-Discovered Aetiology of COVID-19 and Rationale of the Irinotecan+Etoposide Combination Therapy for Critically Ill COVID-19 Patients. (2020). doi:10.20944/PREPRINTS202003.0341.V1
2. Etoposide in Patients With COVID-19 Infection - Full Text View - ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT04356690. (Accessed: 25th April 2020)
3. Clinically Validated Pathology-based AI Prediction of ACE2 Expression as A Predictive Biomarker of COVID-19 Mortality - English. Available at: https://www.demiurge.technology/blog/clinically-validated-pathology-based-ai-prediction-of-ace2-expression-as-a. (Accessed: 25th April 2020)
4. Therapeutic Options Under Investigation | Coronavirus Disease COVID-19. Available at: https://www.covid19treatmentguidelines.nih.gov/therapeutic-options-under-investigation/. (Accessed: 25th April 2020)
About Demiurge Technologies AG
Demiurge Technologies is a research-based AI-biopharmaceutical company that transforms publicly available life science data into precise disease models in areas with unmet medical needs. The company pioneers a self-correcting scientific approach that validates disease models with the accuracy of AI-based predictions of phase 3 clinical trial outcomes. The company also pioneers a self-sustaining business that commercializes disease models by accelerating the AI-based discovery and development of innovative medicines. Demiurge started in 2016 with headquarters in Switzerland.
AI has been an emerging powerful approach to deeper disease understanding and faster drug discovery, yet it must be put to the most rigorous test to prove its worth under public scrutiny. Demiurge has predicted the outcomes of more than 90 phase 3 clinical trials across multiple therapeutic areas and achieved more than 80% accuracy. Furthermore, we have been inviting the public to witness our future predictions of clinical trial outcomes on Twitter (@DemiurgeTech).
Therefore, we officially put forward AI-based discoveries of the precise aetiology and pathology of COVID-19 and the candidate treatments for COVID-19 as scientific hypotheses only and invite the world to validate their potential to solve the unprecedented global crisis posed by COVID-19. Demiurge urges everyone to refrain from believing in the efficacy and safety of any COVID-19 candidate treatments before any clinical data come in.
This material is intended for information purposes only and is provided without any warranty of any kind, either expressed or implied. These statements are not guarantees of future performance, condition or results. Figures and graphs in this presentation are for illustration only and are may not match the actual scale. This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’,‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees. Demiurge Technologies AG (“Demiurge”) undertakes no duty or obligation to publicly update or revise the forward-looking statements or other information contained in this presentation. You should not view information related to the past performance of Demiurge and its affiliates or information about the market, as indicative of future results, the achievement of which cannot be assured. While some information used in this document may have been obtained from various published and unpublished sources considered to be reliable, Demiurge neither guarantees its accuracy or completeness nor accepts liability for any direct or consequential losses arising from its use. Amounts and percentages may reflect rounding adjustments and consequently totals may not appear to sum. None of the information in this presentation does, by itself, constitute an offering or an offering circular according to Article 652a of the Swiss Code of Obligations and is subject to change without notice. Any offer or solicitation with respect to any securities that may be issued by Demiurge will be made only by means of definitive offering memoranda or prospectus, which will be provided to prospective investors and will contain material information that is not set forth herein, including risk factors relating to any such investment. Before making an investment, you must obtain and carefully read all information needed to evaluate the investment, including, but not limited to the documents providing important disclosures regarding risks, fees and expenses. An investment in Demiurge may be volatile and can suffer from adverse or unexpected market moves or other adverse events. Investors may suffer the loss of their entire investment. An investment in Demiurge will be discrete from an investment in any funds or other investment programs managed by Demiurge and the results or performance of such other investment programs is not indicative of the results or performance that will be achieved by Demiurge or such investment programs.